trial

A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia

NCTId NCT07521683
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Enrolling By Invitation
Enrollment 150 (estimated)
Sponsored by NeuShen Therapeutics
Primary completion 2026-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Enrolling By Invitation
Enrollment
150 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2025-10-20
Primary completion
2026-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
NS-136

Sponsors

NeuShen TherapeuticsLead Sponsor

Sites

1 total
Shanghai, China

Linked catalysts

1
A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the T — primary completion2026-11

Facts & assertions

4 sourced
Enrollment
150
Phase
PHASE2
Primary Completion Date
2026-11
Status
ENROLLING_BY_INVITATION
relationships
The graph out of here
drug
NS-136
drug
lead_sponsor
NeuShen Therapeutics
company
indication
Schizophrenia(Acute)
indication